However, the response to these immunotherapies is highly reliant on the specific tumor immune microenvironment, as indicated by the expression of various biomarkers such as PD-L1, tumor-infiltrating lymphocytes (TILs), and tumor mutational burden (TMB). Here, CD274 is linked to neoplasm.